Table 4 Intra-procedural and post angioplasty anticoagulants and anti-platelets used
Studies | Intra-procedural anti-platelets/anti-coagulants | Post procedural/discharge anti-platelets (majority) | Duration of DAPT use | Access site for PCI |
|---|---|---|---|---|
Ayoub 2018 [8] | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
Ito 2018 [9] | Unfractionated heparin | Aspirin, clopidogrel or ticlopidine (DAPT) | ≥ 3 months | Not mentioned |
Kiviniemi 2013 [10] | LMWH (enoxaparin sodium and dalteparin), unfractionated heparin, bivalirudin, and glycoprotein IIb/IIIa inhibitors | Aspirin, clopidogrel and warfarin Or Aspirin and clopidogrel (DAPT) | 1–3 months | Femoral access |
Liu 2018 [11] | Aspirin, clopidogrel, LMWH, glycoprotein IIb/IIIa inhibitors | Aspirin and clopidogrel (DAPT) | short term use without mentioning the exact time duration | Not mentioned |
Overgaard 2008 [12] | Not mentioned | Not mentioned | Not mentioned | Femoral access |
Raphael 2016 [13] | Aspirin, clopidogrel, heparin | Aspirin and clopidogrel (DAPT) | Not mentioned | Femoral > radial access |
Shiraishi 2019 [14] | Aspirin, thienopyridine | Aspirin, clopidogrel, ticlopidine or prasugrel (DAPT) | Not mentioned | Radial > femoral access |
Yadav 2016 [15] | Heparin, bivalirudin, and glycoprotein IIb/IIIa inhibitors, aspirin and clopidogrel | Aspirin, clopidogrel, ticlopidine or prasugrel (DAPT) | Not mentioned | Not mentioned |